Campylobacter pylori--therapy review.
Although Campylobacter pylori is sensitive to many antibiotics in vitro, few are effective in vivo. Furthermore, treatment regimens which successfully clear the organism in vivo are associated with high recurrence rates when assessed one month following treatment. On the other hand, 85% of those individuals who are C. pylori negative 1 month after the cessation of therapy remain negative at 12 months and the infection can be considered to be eradicated. Treatment with certain bismuth salts appears to be the most useful monotherapy, eradicating the organism in approximately 19% whilst dual therapy with bismuth plus ampicillin or tinidazole is more effective, eradicating infection in 32% and 78% respectively. Preliminary data suggest that triple therapy with bismuth, amoxicillin and metronidazole, or bismuth, tetracycline and metronidazole eradicates the infection in over 90%.
Axon
A T
AT
Gastroenterology Unit, General Infirmary, Leeds, England.
D000863:Antacids / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001729:Bismuth / Q000627:therapeutic use; D002169:Campylobacter Infections / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D006801:Humans; D008795:Metronidazole / Q000627:therapeutic use; D009942:Organometallic Compounds / Q000627:therapeutic use; D012459:Salicylates / Q000627:therapeutic use; D020156:Salicylic Acid
D000863:Antacids; D000900:Anti-Bacterial Agents; D009942:Organometallic Compounds; D012459:Salicylates; D008795:Metronidazole; C002791:bismuth tripotassium dicitrate; D020156:Salicylic Acid; D001729:Bismuth